Paidion Research, a new CRO focused exclusively on pediatrics and specializing in NICU and PICU populations (neonatal and pediatric intensive care), recently opened for business. Headquartered in Durham, N.C., Paidion combines pediatric clinical pharmacology experience with innovative pediatric regulatory strategies and trial methodologies to provide best-in-class service to drug and device development partners in industry, government, academia and nonprofits.
Recently, the FDA and EMA made significant changes in their regulations and now require a pediatric component for all drug research. Paidion is a global CRO that helps organizations develop and execute clinical trials that meet the new pediatric requirements quickly, efficiently and cost-effectively.
Led by veteran research executives with more than 30 years of experience in academia, CROs and pharmaceutical companies, Paidion’s project teams deliver cost-effective, efficient and timely clinical trial results for phase I/II, phase III and long-term follow-up pediatric studies.